Results 31 to 40 of about 69,829 (275)

Evaluation of Ribavirin–Poloxamer Microparticles for Improved Intranasal Absorption

Pharmaceutics, 2021
Ribavirin is a water-soluble antiviral compound which, owing to its inability to cross the blood–brain barrier, has limited effectiveness in treating viruses affecting the central nervous system.
Dipy M. Vasa, Zainab Bakri, Maureen D. Donovan, Lauren A. O’Donnell, Peter L. D. Wildfong   +4 more
doaj   +1 more source

Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA

Proceedings of the National Academy of Sciences of the United States of America, 2017
Significance Emerging coronaviruses (CoVs; severe acute respiratory syndrome-CoV and Middle East respiratory syndrome-CoV) pose serious health threats globally, with no specific antiviral treatments available.
F. Ferron, Lorenzo Subissi, Ana Theresa Silveira De Morais, N. Le, M. Sévajol, L. Gluais, E. Decroly, C. Vonrhein, G. Bricogne, B. Canard, I. Imbert   +10 more
semanticscholar   +1 more source

Influence of Ribavirin Serum Levels on Outcome of Antiviral Treatment and Anemia in Hepatitis C Virus Infection. [PDF]

PLoS ONE, 2016
BACKGROUND:Ribavirin blood levels vary considerably between patients with standard weight-based dosing. Their impact on sustained virological response (SVR) with pegylated interferon and ribavirin is controversial, but has mostly been studied before the ...
Thomas Kuntzen, Sereina Kuhn, Daniela Kuntzen, Burkhardt Seifert, Beat Müllhaupt, Andreas Geier   +5 more
doaj   +1 more source

Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post‐liver transplantation recurrence

Hepatology, 2016
Chronic hepatitis C virus (HCV) infection with advanced cirrhosis or post‐liver transplantation recurrence represents a high unmet medical need with no approved therapies effective across all HCV genotypes. The open‐label ALLY‐1 study assessed the safety
F. Poordad, E. Schiff, J. Vierling, C. Landis, R. Fontana, Rong Yang, F. Mcphee, E. Hughes, S. Noviello, E. Swenson   +9 more
semanticscholar   +1 more source

Low-Dose Ribavirin Treatments Attenuate Neuroinflammatory Activation of BV-2 Cells by Interfering with Inducible Nitric Oxide Synthase

Analytical Cellular Pathology, 2015
Microglia play a key role in defending central nervous system from various internal and external threats. However, their excessive and/or chronic activation is associated with deleterious effects in a variety of neurodegenerative diseases. Previously, we
Iva Bozic, Danijela Savic, Marija Jovanovic, Ivana Bjelobaba, Danijela Laketa, Nadezda Nedeljkovic, Mirjana Stojiljkovic, Sanja Pekovic, Irena Lavrnja   +8 more
doaj   +1 more source

Influence of chemotherapy on development and production of virus free in vitro strawberry plants

Horticultural Science, 2019
The objective of the study was to determine effects of ribavirin on development and health status of in vitro grown strawberry cultivars 'Honeoye' and 'Elkat' infected with viruses Strawberry mild yellow-edge virus (SMYEV), Tomato ringspot virus (ToRSV ...
Jiří Sedlák, František Paprštein, Jana Suchá   +2 more
doaj   +1 more source

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.

New England Journal of Medicine, 2014
BACKGROUND Interferon-containing regimens for the treatment of hepatitis C virus (HCV) infection are associated with increased toxic effects in patients who also have cirrhosis.
F. Poordad, C. Hézode, R. Trinh, K. Kowdley, S. Zeuzem, K. Agarwal, M. Shiffman, H. Wedemeyer, T. Berg, E. Yoshida, X. Forns, Sandra S. Lovell, Barbara Da Silva-Tillmann, Christine A. Collins, A. Campbell, T. Podsadecki, B. Bernstein   +16 more
semanticscholar   +1 more source

Efficacy of Sofosbuvir and Velpatasvir, With and Without Ribavirin, in Patients With Hepatitis C Virus Genotype 3 Infection and Cirrhosis.

Gastroenterology, 2018
BACKGROUND & AIMS In phase 3 trials and real-world settings, smaller proportions of patients with genotype 3 hepatitis C virus (HCV) infection and cirrhosis have a sustained virologic response 12 weeks after treatment (SVR12) with the combination of ...
R. Esteban, J. Pineda, J. Calleja, M. Casado, Manuel Rodríguez, J. Turnes, L. M. Morano Amado, R. Morillas, X. Forns, J. M. Pascasio Acevedo, R. Andrade, A. Rivero, J. Carrión, S. Lens, M. Riveiro‐Barciela, B. McNabb, Gulan Zhang, G. Camus, L. Stamm, D. Brainard, G. Subramanian, M. Buti   +21 more
semanticscholar   +1 more source

Bee products as alternatives in the treatment of viral infections

Journal of the Science of Food and Agriculture, EarlyView.
Abstract Medicines used in the treatment of viral infections usually reduce symptoms. There is a need to develop drugs that inhibit the viruses and do not merely relieve the symptoms. Natural bee products possess many pharmacological properties and are widely used in folk medicine. There are many studies on the antibacterial effects of bee products but
Michał Otręba, Łukasz Marek, Jerzy Stojko, Anna Rzepecka‐Stojko   +3 more
wiley   +1 more source

Sofosbuvir and Ribavirin Therapy for Children Aged 3 to <12 Years With Hepatitis C Virus Genotype 2 or 3 Infection

Hepatology, 2019
Currently, the only approved hepatitis C virus (HCV) treatment for children aged
P. Rosenthal, K. Schwarz, R. Gonzalez-Peralta, Chuan-Hao Lin, D. Kelly, S. Nightingale, W. Balistreri, S. Bansal, M. Jonas, B. Massetto, D. Brainard, C. Hsueh, J. Shao, Bandita Parhy, S. Davison, C. Feiterna-Sperling, L. Gillis, G. Indolfi, E. Sokal, K. Murray, S. Wirth   +20 more
semanticscholar   +1 more source